{"schema_version":"secwatch.filing_event.v1","accession":"0001447362-24-000006","form_type":"8-K","ticker":"CSTL","cik":"0001447362","company_name":"CASTLE BIOSCIENCES INC","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.220531+00:00","generated_at":"2026-06-07T02:11:05.023323+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Castle Biosciences expects 2023 revenue >$210M, exceeding guidance; test volume +59%","bullets":["Expects 2023 total revenue >$210M, at least 53% growth over 2022, surpassing prior guidance floor of $200M.","Delivered 70,429 total test reports in 2023, up 59% YoY; Q4 reports 20,284, up 60% YoY.","TissueCypher Barrett's Esophagus test reports surged 328% YoY in 2023; IDgenetix up 236%.","Year-end cash, equivalents and short-term investments expected ~$243M.","Preliminary results, subject to audit completion; final results may differ."],"urls":{"canonical":"https://secwatch.observer/filing/0001447362-24-000006","json":"https://secwatch.observer/filing/0001447362-24-000006.json","markdown":"https://secwatch.observer/filing/0001447362-24-000006.md","text":"https://secwatch.observer/filing/0001447362-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1447362/000144736224000006/0001447362-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1447362/000144736224000006/cstl-20240107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:11:05.023323+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea50b7f2d74bb02159b8b44d3ee17bce79bf18b0","claim":"CASTLE BIOSCIENCES INC reported the fourth quarter and year ended Dec. 31, 2023 results: revenue more than $210 million.","evidence_excerpt":"contains --- EX-99.2 (EX-99.2) --- Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results Expect to deliver 2023 total revenue of more than $210 million, at least 53% growth over 2022 Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash, cash equivalents and marketable investment","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1447362/000144736224000006/0001447362-24-000006-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended Dec. 31, 2023"},{"label":"Revenue","value":"more than $210 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}